Overactive Bladder Treatment Market Giants: Strategies, Financial Performance, and Future Outlook

-

The global overactive bladder treatment market is projected to reach USD 4.2 Billion by 2027 from USD 3.5 Billion in 2022, at a CAGR of 3.6% during the forecast period Major factors driving the market growth are rising prevalence of overactive bladder syndrome across the globe. Furthermore, launch of novel drugs with lesser side-effects coupled with adoption of technologically advanced treatment options for OAB treatment are also expected to support market growth in the coming years.

Overactive bladder treatment market is fragmented and competitive in nature, several market players are adopting strategies to sustain market competition. The company offerings range from, various drugs, devices and botox that have larger geographic reach along with high product flexibility. Prominent players in the global overactive bladder treatment market are Astellas Pharma (Japan), Teva Pharmaceutical Industries (Israel), Pfizer (US), Medtronic (Ireland), AbbVie (US), Viatris (US), Hisamitsu Pharmaceutical (Japan), Johnson & Johnson Services (US), Endo Pharmaceuticals (Ireland), and among others.

ASTELLAS PHARMA (JAPAN)

Astellas Pharma is a Japanese multinational pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co. Astellas Pharma is engaged in the research, development, manufacturing, import, and export of pharmaceutical products. It is one of the leading players operating in the overactive bladder treatment market globally. The company provides two major drugs—Betanis/Myrbetriq/BETMIGA and VESIcare. Myrbetriq is one of the most prescribed medications for overactive bladder disorders. The company has its research & development base in Japan and R&D centers in Europe and other countries across the Asia Pacific. The company operates in more than 70 countries across the globe.

PFIZER (US)

Pfizer is a leading global pharmaceutical company. It develops medicines for a wide range of therapeutic areas, such as metabolic & cardiovascular diseases, inflammation & immunology, neuroscience & pain, oncology, rare diseases, and vaccines. The company operates through three distinct business segments: Biopharma, Pfizer CentreOne, and Consumer Healthcare. In July 2019, the Consumer Healthcare business, an OTC medicines business, was combined with GSK’s Consumer Healthcare business to form a new Consumer Healthcare JV.

The product, TOVIAZ, comes under the Internal Medicine segment of the Biopharma business. The company markets its product Detrol via Viatris. Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.

ABBVIE INC. (US)

AbbVie is a diversified research-based biopharmaceutical company with a comprehensive product portfolio that has leadership positions across immunology, hematologic oncology, neuroscience, aesthetics, and eye care. In May 2020, the company acquired Allergan plc, an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention, and urology. Allergan provides BOTOX therapeutics, including Vraylar and Ubrelvy. The company provides Enablex, extended-release tablets for overactive bladder treatment.

AbbVie operates through a single business segment. The company’s products are sold worldwide directly to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The company serves in more than 100 countries across the globe.

Related Links

https://www.marketsandmarkets.com/Market-Reports/overactive-bladder-treatment-market-219938791.html

https://www.marketsandmarkets.com/ResearchInsight/overactive-bladder-treatment-market.asp

https://www.marketsandmarkets.com/PressReleases/overactive-bladder-treatment.asp

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more